Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin

Summary

Little study has been performed on the effect of vitamin K intake on the variability of warfarin’s anticoagulant effects over long period of time. We estimated average vitamin K intake in the patients taking warfarin and evaluated its relation with the stability of anticoagulation effect. We estimated average daily vitamin K intake based on a three-day food diary in 66 patients taking warfarin regularly for ≥one year and divided them into three groups of equal number according to vitamin K intake. Stability of anticoagulant effect was compared in these groups using the coefficient of variation (CV) of the prothrombin time expressed in international normalised ratio (INR) and the CV of warfarin doses. Median daily vitamin K intake was 161.3 μg/day (31.3 μg/day – 616.6 μg/day). CVs of both INR and warfarin doses were negatively and independently correlated with dietary vitamin K intake (r=-0.293, p=0.017 and r= –0.350, p=0.004, respectively). CV of INR was significantly different among three groups of vitamin K intake (p<0.05 in ANOVA). High vitamin K intake (>195.7 μg/day) group had lower CV of INR than the low intake (<126.5 μg/day) group (19.2 ± 8.96 % vs. 25.5 ± 8.61 %, p<0.05). CV of warfarin doses was also significantly different among the groups (p<0.05 in Jonckheere-Terpstra test). However, the significance of difference between high and low vitamin intake groups was marginal (p=0.046 in Mann-Whitney test). In conclusion, long-term anticoagulation effect of warfarin is more stable in the patients who take greater than a certain amount of dietary vitamin K.

Footnote: The content of this paper was submitted as partial fulfillment of the requirement for the degree of Master of Medical Science (Kim KH) to the Kyungpook National University.

Keywords

Vitamin K - oral anticoagulant - stability

• References

• 1 Hirsh J, Fuster V, Ansell J. et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
• 2 Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978; 15: 19-26.
• 3 Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530-547.
• 4 Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127-132.
• 5 Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005; 39: 1008-1012.
• 6 Schurgers LJ, Shearer MJ, Hamulyák K. et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104: 2682-2689.
• 7 Franco V, Polanczyk CA, Clausell N. et al. Role of dietary Vitamin K intake in chronic oral anticoagulation: Prospective evidence from observational and randomized protocols. Am J Med 2004; 116: 651-656.
• 8 Lubetsky A, Dekel-Stern E, Chetrit A. et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81: 396-399.
• 9 Khan T, Wynne H, Wood P. et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124: 348-354.
• 10 Cushman M, Booth SL, Possidente CJ. et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-577.
• 11 Sconce E, Avery P, Wynne H. et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109: 2419-2423.
• 12 Rural Resource Development institute, National Academy of Agricultural Science.. Food composition table. 7^th Ed. Seoul: Rural Development Administration (Korea); 2006
• 13 The Korean Nutrition Society. CAN PRO 3.0. Seoul, 2006.
• 14 de Assis MC, Rabelo ER, Avila CW. et al. Improved oral anticoagulation after a dietary vitamin K-guided strategy : a randomized controlled trial. Circulation 2009; 120: 1115-1122.
• 15 Johnson MA. Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. Nutr Rev 2005; 63: 91-97.
• 16 Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530-547.
• 17 Gersovitz M, Madden JP, Smiciklas-Wright H. Validity of the 24-hr. dietary recall and seven-day record for group comparisons. J Am Diet Assoc 1978; 73: 48-55.
• 18 Price R, Fenton S, Shearer MJ. et al. Daily and seasonal variation in phylloquinone (vitamin K₁) intake in Scotland. Proc Nutr Soc 1996; 55: 244A.
• 19 Wiens L, Schulzer M, Chen C. et al. Reliability and validity of the SmartDiet Canadian version questionnaire. J Am Diet Assoc 2010; 110: 101-105.
• 20 The International Warfarin Pharmacogenetics Consortium.. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
• 21 Scott SA, Edelmann L, Kornreich R. et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495-500.